Market Overview

UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential

Share:
Related XOMA
Earnings Scheduled For March 9, 2016
Every Biotech Catalyst Wedbush Is Watching In 2016
Buy XOMA Corporation For Its Monoclonal Antibodies To Treat Congenital Hyperinsulinism And Refractory Prolactinoma (Seeking Alpha)

Credit Suisse initiated coverage on XOMA Corporation (NASDAQ: XOMA) with an Outperform rating and a $4 price target.

Credit Suisse commented, "Xoma has recently refocused its efforts and bolstered its balance sheet to advance the development of gevokizumab for multiple indications. Retained marketing rights, a well-designed clinical program, and multiple data readouts in the next 12 months provide for upside potential, although with speculative risk."

XOMA Corporation closed at $2.67 on Monday.

Latest Ratings for XOMA

DateFirmActionFromTo
Jul 2015JefferiesDowngradesBuyHold
Jun 2015SusquehannaDowngradesPositiveNeutral
May 2015Credit SuisseAssumesNeutral

View More Analyst Ratings for XOMA
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (XOMA)

View Comments and Join the Discussion!